Live Breaking News & Updates on Only Complete Long Acting Injectable

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7% and adjusted operational growth of 7.9% Earnings per share of $1.93 decreasing 16.. ....

Joaquin Duato , Prnewswire Johnson , Interventional Solutions , Exchange Commission , Skin Health Beauty , Consumer Health Company , Consumer Health , Company Consumer Health , Chief Executive , Medical Devices , Skin Health , General Surgery , Advanced Surgery , Current Reports , Quarterly Reports , Annual Reports , First Cell Therapy , Refractory Multiple , Use Every Two Months , Only Long Acting , Only Complete Long Acting Injectable , Streamlined Process , Submits Marketing Authorisation Application , European Medicines Agency Seeking Approval , Bispecific Antibody Teclistamab , Seeks Approval ,